First Scientific Receives $1 Million Equity Funding

Apr 03, 2001, 01:00 ET from First Scientific, Inc.

    OGDEN, Utah, April 3 /PRNewswire/ -- First Scientific, Inc., (OTC: FSFI),
 a developer and supplier of break-through topical skin care technologies and
 products, today announced that it received $1 million in new equity funding.
 The company announced that Todd Heiner, a director of the company, has
 invested $1 million in a privately negotiated transaction.  The funds will be
 used to support the growth and continuing operations of the company.  Aspen
 Capital Resources, LLC, will continue to hold a preferred position in First
 Scientific.
     "With increasing customer orders requiring additional capital, this
 investment gives us the necessary funds to meet our obligations and continue
 to meet the objectives of our business plan," said Randy Hales, president and
 CEO of First Scientific.
     Additional details of the equity funding will be disclosed in First
 Scientific's next quarterly report, to be filed with the Securities and
 Exchange Commission on or about May 15, 2001.
 
     About First Scientific(TM):
     First Scientific, Inc., (OTC: FSFI), of Ogden, Utah, is a developer and
 supplier of break-through antimicrobial and skin care protective solutions for
 health care, food service, and other workplace, public and home environments.
 First Scientific's MicrobNZ(TM) antimicrobial technology and other skin
 healing and skin care products are available through third-party distributors
 and manufacturers and direct to customers under the ProCleanse(TM) product
 label, in addition to being available online at the company's Web site.  First
 Scientific's division, PureSoft Solutions, distributes the MicrobNZ(TM)
 antimicrobial technology under the PureCleanse(TM) label.  First Scientific
 can be reached at (801) 393-5781 or (888) 304-2092; via email:
 firstsci@firstscientific.com; or by visiting www.firstscientific.com or
 www.puresoft.ws.
 
     This release contains forward-looking statements within the meaning of
 Section 27A of the Securities Act of 1933 and Section 21E of the Securities
 Exchange Act of 1934 as well as historical information.  Forward-looking
 statements may involve known or unknown risks, uncertainties and other factors
 that may cause the company's actual results and performance to differ
 materially from the company's outlook.  Important factors that could cause
 actual results to differ include but are not limited to: outlook for health
 care customers, demand for products, differences in anticipated and actual
 product introduction dates and the ultimate success of those products in the
 marketplace, among other things.  Such forward-looking statements speak only
 as of the date of this release.  The company assumes no obligation to update
 or revise any forward-looking statements. Readers are urged to carefully
 review and consider the various disclosures made by the company in the
 company's periodic reports on Forms 10-KSB, 10-QSB and 8-K filed with the
 Securities and Exchange Commission.
 
     First Scientific, MicrobNZ and ProCleanse are trademarks of First
 Scientific, Inc.  All other trademarks and registered trademarks are the
 property of their respective owners.
 
     For further information please contact: Media Relations, Melissa Clyne, PR
 Mgr., 801-486-6763, mclyne@firstscientific.com, or Investor Relations, Randall
 L. Hales, CEO, 801-393-5781, or 888-335-3329, rhales@firstscientific.com, both
 of First Scientific, Inc.
 
 

SOURCE First Scientific, Inc.
    OGDEN, Utah, April 3 /PRNewswire/ -- First Scientific, Inc., (OTC: FSFI),
 a developer and supplier of break-through topical skin care technologies and
 products, today announced that it received $1 million in new equity funding.
 The company announced that Todd Heiner, a director of the company, has
 invested $1 million in a privately negotiated transaction.  The funds will be
 used to support the growth and continuing operations of the company.  Aspen
 Capital Resources, LLC, will continue to hold a preferred position in First
 Scientific.
     "With increasing customer orders requiring additional capital, this
 investment gives us the necessary funds to meet our obligations and continue
 to meet the objectives of our business plan," said Randy Hales, president and
 CEO of First Scientific.
     Additional details of the equity funding will be disclosed in First
 Scientific's next quarterly report, to be filed with the Securities and
 Exchange Commission on or about May 15, 2001.
 
     About First Scientific(TM):
     First Scientific, Inc., (OTC: FSFI), of Ogden, Utah, is a developer and
 supplier of break-through antimicrobial and skin care protective solutions for
 health care, food service, and other workplace, public and home environments.
 First Scientific's MicrobNZ(TM) antimicrobial technology and other skin
 healing and skin care products are available through third-party distributors
 and manufacturers and direct to customers under the ProCleanse(TM) product
 label, in addition to being available online at the company's Web site.  First
 Scientific's division, PureSoft Solutions, distributes the MicrobNZ(TM)
 antimicrobial technology under the PureCleanse(TM) label.  First Scientific
 can be reached at (801) 393-5781 or (888) 304-2092; via email:
 firstsci@firstscientific.com; or by visiting www.firstscientific.com or
 www.puresoft.ws.
 
     This release contains forward-looking statements within the meaning of
 Section 27A of the Securities Act of 1933 and Section 21E of the Securities
 Exchange Act of 1934 as well as historical information.  Forward-looking
 statements may involve known or unknown risks, uncertainties and other factors
 that may cause the company's actual results and performance to differ
 materially from the company's outlook.  Important factors that could cause
 actual results to differ include but are not limited to: outlook for health
 care customers, demand for products, differences in anticipated and actual
 product introduction dates and the ultimate success of those products in the
 marketplace, among other things.  Such forward-looking statements speak only
 as of the date of this release.  The company assumes no obligation to update
 or revise any forward-looking statements. Readers are urged to carefully
 review and consider the various disclosures made by the company in the
 company's periodic reports on Forms 10-KSB, 10-QSB and 8-K filed with the
 Securities and Exchange Commission.
 
     First Scientific, MicrobNZ and ProCleanse are trademarks of First
 Scientific, Inc.  All other trademarks and registered trademarks are the
 property of their respective owners.
 
     For further information please contact: Media Relations, Melissa Clyne, PR
 Mgr., 801-486-6763, mclyne@firstscientific.com, or Investor Relations, Randall
 L. Hales, CEO, 801-393-5781, or 888-335-3329, rhales@firstscientific.com, both
 of First Scientific, Inc.
 
 SOURCE  First Scientific, Inc.